Literature DB >> 8205537

Functional insulin and insulin-like growth factor-1 receptors are preferentially expressed in multiple myeloma cell lines as compared to B-lymphoblastoid cell lines.

G G Freund1, D T Kulas, B A Way, R A Mooney.   

Abstract

While IGF-1 plays a role in early B-cell development, little is known of insulin and insulin-like growth factor-1 (IGF-1) action in post-marrow B-cells. Recently, our laboratory demonstrated that mouse and human multiple myeloma (MM) cell lines possess functional insulin receptors (IRs) and IGF-1 receptors (IGF-1Rs). In this study, we show that responsiveness to insulin and IGF-1 is more developed in human MM cell lines than in human B-lymphoblastoid cell lines. Two human MM cell lines (U266 and RPMI 8226) were compared to three B-lymphoblastoid cell lines [Epstein-Barr virus immortalized B-cells (EBV), a Burkitt lymphoma cell line (Ramos), and a non-EBV lymphoblastoid cell line (HS Sultan)]. Surface IR and IGF-1R expression, measured by flow cytometry, demonstrated that the MM cell lines expressed more IRs and IGF-1Rs than did the EBV, Ramos, or HS Sultan cell lines. In vitro receptor kinase activity of affinity-purified receptors showed that the MM cells had more phosphorylated receptors than did the EBV, Ramos, or HS Sultan cells. Intracellular receptor signaling was also markedly different between the two cell groups. Whole cell phosphorylation studies showed that MM cells possessed not only hormone-dependent receptor autophosphorylation (M(r) 97,000) but also substrate phosphorylation (M(r) 185,000; 60,000). The lymphoblastoid cells, while demonstrating receptor autophosphorylation (IR autophosphorylation in the EBV cell line at 200 nM hormone was similar to MM receptor phosphorylation at 2 nM), lacked hormone-responsive substrates. The MM cell lines contained significantly more hormone-stimulated phosphatidylinositol 3-kinase (PI 3-kinase) activity than the B-lymphoblastoid cell lines. In the MM cells, PI 3-kinase was activated by at least 10-fold, but, in the B-lymphoblastoid cell lines, it was activated by no more than 2-fold. Hormone-responsive glucose metabolism was also greater in the MM cell lines. In the U266 cells, insulin increased lactate production 62 +/- 9 and 101 +/- 12% (mean +/- SE) at concentrations of 2 nM and 200 nM, respectively. IGF-1 produced 72 +/- 9 and 99 +/- 13% increases at similar concentrations. In the 8226 cells, insulin increased lactate production 4 +/- 4 and 36 +/- 15% at 2 and 200 nM, respectively. IGF-1 produced a 13 +/- 6 and 70 +/- 18% increase. In the EBV and Ramos cells, neither hormone increased lactate production by more than 10 +/- 3%.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8205537

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

Review 1.  Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?

Authors:  Terry J Smith
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

2.  Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.

Authors:  Deborah J Kuhn; Zuzana Berkova; Richard J Jones; Richard Woessner; Chad C Bjorklund; Wencai Ma; R Eric Davis; Pei Lin; Hua Wang; Timothy L Madden; Caimiao Wei; Veerabhadran Baladandayuthapani; Michael Wang; Sheeba K Thomas; Jatin J Shah; Donna M Weber; Robert Z Orlowski
Journal:  Blood       Date:  2012-08-29       Impact factor: 22.113

3.  Colocalisation of insulin and IGF-1 receptors in cultured rat sensory and sympathetic ganglion cells.

Authors:  S N Karagiannis; R H King; P K Thomas
Journal:  J Anat       Date:  1997-10       Impact factor: 2.610

4.  Lactic acidosis and hypoglycemia as markers of disease progression of multiple myeloma: A case report.

Authors:  Caroline Ziegler; Lev Volkov; Rémy Marnai; Guilhem Courte; Aurélie Cravoisy; Marie Conrad; Lionel Nace; Agnès Melone; Aurore Perrot; Sébastien Gibot
Journal:  EJHaem       Date:  2021-05-05

5.  Study on the possibility of insulin as a carrier of IUdR for hepatocellular carcinoma-targeted therapy.

Authors:  Xiao-Hong Ou; An-Ren Kuang; Xian Peng; Yu-Guo Zhong
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

6.  B cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis.

Authors:  Raymond S Douglas; Vibharavi Naik; Catherine J Hwang; Nikoo F Afifiyan; Andrew G Gianoukakis; Daniel Sand; Shweta Kamat; Terry J Smith
Journal:  J Immunol       Date:  2008-10-15       Impact factor: 5.422

7.  The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma.

Authors:  W Wu; K Merriman; A Nabaah; N Seval; D Seval; H Lin; M Wang; M H Qazilbash; V Baladandayuthapani; D Berry; R Z Orlowski; M-H Lee; S-C J Yeung
Journal:  Br J Cancer       Date:  2014-06-12       Impact factor: 7.640

8.  Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model.

Authors:  E Menu; R Kooijman; E Van Valckenborgh; K Asosingh; M Bakkus; B Van Camp; K Vanderkerken
Journal:  Br J Cancer       Date:  2004-03-08       Impact factor: 7.640

Review 9.  The Relation of Obesity-Related Hormonal and Cytokine Levels With Multiple Myeloma and Non-Hodgkin Lymphoma.

Authors:  H Dean Hosgood; Marc J Gunter; Neil Murphy; Thomas E Rohan; Howard D Strickler
Journal:  Front Oncol       Date:  2018-04-16       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.